Tonsil surgery is reduced with Bactek-MV130

Tonsil surgery is reduced with Bactek-MV130

{$excerpt:n}

04/2019. Bactek-MV130 reduces tonsillectomies

According to a recent study published in the scientific journal Human Vaccines & Immunotherapeutics by Luis-Amando García González and Federico Arrutia Díez, the combination of an antibiotic treatment with Bactek-MV130 significantly reduces the need of tonsils removal in adult patients with recurrent tonsillitis.

The study, conducted at Hospital Valle del Nalón and Hospital de Cabueñes (Asturias, Spain) over 88 patients, compared a group treated with antibiotics alone to another treated with antibiotics plus Bactek-MV130.

Bactek-MV130 is a polybacterial mucosal vaccine produced by INMUNOTEK that is administered sublingually. Bactek-MV130 acts as a TIbV (trained immunity-based vaccine).  These vaccines may confer a broad anti-infectious protection, as outlined recently in Frontiers in Immunology.

Download the article

La entrada Tonsil surgery is reduced with Bactek-MV130 se publicó primero en Inmunotek.


Source: Inmunotek News

Visit of the Regional Minister of Health

Visit of the Regional Minister of Health

{$excerpt:n}

03/2019. The Regional Minister of Health visits INMUNOTEK

The Regional Minister of Health of the Community of Madrid, Enrique Ruiz Escudero, visited the facilities of INMUNOTEK in Tecnoalcalá (Alcalá de Henares – Madrid). 

On March 15, the Regional Minister of Health of the Community of Madrid, Enrique Ruiz Escudero, visited INMUNOTEK after being awarded the prize for the best Innovative Company granted by CEIM-CEOE.

José Luis Subiza, CEO-President, made a brief presentation of the company and the R&D projects that INMUNOTEK is developing in collaboration with different hospitals and centers in the Community of Madrid. He highlighted the research lines that the company has in immunotherapy for allergic, infectious and neoplastic diseases. He took the opportunity to present the INMUNOTEK Foundation, recently created, and its main objectives. Then, they made a tour to the production facilities, in order to learn about the manufacturing processes and control of their products.

The visit was accompanied by Luisa María Fernández, General Director of Madrid Activa, the public management company of Tecnoalcalá, and the managers of INMUNOTEK.


La entrada Visit of the Regional Minister of Health se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK revalidates its Innovative SME stamp

INMUNOTEK revalidates its Innovative SME stamp

{$excerpt:n}

03/2019. Innovative SME stamp

INMUNOTEK revalidates its Innovative SME stamp.

INMUNOTEK maintains its R&D effort working in a number of research projects that have allowed the revalidation of the Innovative SME stamp granted in 2015 by the Spanish Government.

Currently, INMUNOTEK has ongoing projects with different research centers, including the Complutense University of Madrid (Immunology, Biochemistry and Cell Biology), University of Salamanca, CNIC (National Center for Cardiovascular Research), ISCIII (Carlos III Health Institute) and CIB (Biological Research Center).

The public record of innovative SMEs depends on the Directorate for Innovation and Competitiveness of the Ministry of Economy and Competitiveness of Spain. It is granted by the Order ECC / 1087/2015 where the requirements for its obtention are described.

La entrada INMUNOTEK revalidates its Innovative SME stamp se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK Awards

You need to login to view this content. Please Login

TIbV – Trained Immunity-based Vaccines

You need to login to view this content. Please Login

iGEM 2018 competition

iGEM 2018 competition

{$excerpt:n}

11/2018. The iGEM-Madrid team awarded

The project presented by the iGEM-Madrid team has been awarded with a silver medal and nominated as the best project of its category in the iGEM 2018 competition held in Boston. 

The iGEM competition originated in 2003 at the Massachusetts Institute of Technology in order to encourage the development of biosynthetic applications among students and recent graduates. At present, this competition has an international dimension with the participation of hundreds of teams from more than 40 countries.

This year a team from Madrid (iGEM-Madrid) has been presented for the first time, made up of students and recent graduates from various faculties of the Complutense University of Madrid. His project IoBT (Internet of Bio-Things) is an integration of engineering, biosensors and data transfer in real time over the internet for the quantification of allergens in the air of cities. His prototype has earned recognition in the competition held in Boston where more than 300 teams from all over the world have performed.

The iGEM-Madrid team has been sponsored by INMUNOTEK.

+info 

 

The iGEM-Madrid team: Francisco Javier Quero Lombardero, Laura Armero Hernandez, Rodrigo Hernández Cifuentes, Iván Martín Hernández, Borja Sánchez Clemente, Ignacio Albert Smet, Guillermo Fernández Rodríguez, Gonzalo Saiz Gonzalo. 

La entrada iGEM 2018 competition se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK awarded by CEIM as best innovative company

INMUNOTEK awarded by CEIM as best innovative company

{$excerpt:n}

10/2018. INMUNOTEK at the CEIM awards

INMUNOTEK is awarded as Best Innovative Company and distinguished as one of the three companies with the largest International Expansion, in the first edition of the CEIM Awards, granted by the Confederation of Entrepreneurs of Madrid – CEOE, Spain.

This recognition is granted to companies that have stood out during the year, both for their contribution to economic development, job creation and for their work at the service of the community. Mr. Javier Ruiz, Deputy Minister of Economy and Competitiveness of the Community of Madrid has been in charge of giving the award to Dr. Enrique Fernández Caldas, Scientific Director of INMUNOTEK.

The award ceremony was attended by the president of CEIM, Juan Pablo Lázaro, the president of the Chamber of Commerce, Ángel Asensio, institutional representatives, prominent personalities and other businessmen, among which Pedro Manuel Rollán, Vice President of the Community from Madrid; José Ignacio Goirigolzarri, president of Bankia; Clemente González, president of IFEMA, Fernando Martínez, director of Fundación Universidad-Empresa, some of whom are in charge of awarding the prizes to the winners.

Entrega de premios CEIM

The president of CEIM, Juan Pablo Lázaro, highlighted the work of the participating companies and their projects that contribute to the momentum and dynamism of the Spanish economy. He praised the daily effort they make to develop their work. “They are an example for all entrepreneurs and for this reason we have wanted to recognize them with these awards”.

The CEIM Awards are part of the 40th anniversary of the Confederation of Entrepreneurs of Madrid.

+ info

La entrada INMUNOTEK awarded by CEIM as best innovative company se publicó primero en Inmunotek.


Source: Inmunotek News

Novel allergoid-mannan vaccine in veterinary medicine

Novel allergoid-mannan vaccine in veterinary medicine
{$excerpt:n}

10/2018. A pilot study in dogs with atopic dermatitis

It has been published in Veterinary Dermatology a clinical study with a novel vaccine for the treatment of canine atopic dermatitis developed by INMUNOTEK.

Canine atopic dermatitis is an allergic disease caused by sensitization to different allergens including mites.  It can be treated by specific allergen immunotherapy. This study assess for the first time a vaccine consisting of polymers of mite allergens (D. farinae) conjugated with mannan derived from Saccharomyces cerevisiae. These glyco-conjugates are hypoallergenic and target dendritic cells (the cells of the immune system that initiate the immune response). The results of this trial are encouraging for the new preparation since they indicate a rapid clinical improvement with a reduced number of doses without safety concerns. 

Download the paper

Related bibliography:

Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines.

Manzano AI, Javier Cañada F, Cases B, Sirvent S, Soria I, Palomares O, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Subiza JL. Glycoconj J. 2016 Feb;33(1):93-101. doi: 10.1007/s10719-015-9640-4. Epub 2015 Nov 25.

Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1.

Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, Reche PA, López-Relaño J, Martínez-Naves E, Cañada FJ, Jiménez-Barbero J, Subiza J, Casanovas M, Fernández-Caldas E, Subiza JL, Palomares O. J Allergy Clin Immunol. 2016 Aug;138(2):558-567.e11. doi: 10.1016/j.jaci.2016.02.029. Epub 2016 Apr 13

Dendritic cell targeting with C-type lectins for improvement of allergen immunotherapy.

Schülke S, Vieths S. J Allergy Clin Immunol. 2016 Aug;138(2):568-70. doi: 10.1016/j.jaci.2016.06.006. Epub 2016 Jun 23.

Human basophils may not undergo modulation by DC-SIGN and mannose receptor–targeting immunotherapies due to absence of receptors.

Das M, Galeotti C, Stephen-Victor E, Karnam A, Kaveri SV, Bayry J. J Allergy Clin Immunol. 2017 Apr;139(4):1403-1404.e1. doi: 10.1016/j.jaci.2016.09.062. Epub 2017 Jan 11.

Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine.

Soria I, Alvarez J, Manzano AI, López-Relaño J, Cases B, Mas-Fontao A, Cañada FJ, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Palomares O, Viñals-Flórez LM, Subiza JL. Vet Immunol Immunopathol. 2017 Aug;190:65-72. doi: 10.1016/j.vetimm.2017.07.004. Epub 2017 Jul 23.

Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice.

Soria I, López-Relaño J, Viñuela M, Tudela JI, Angelina A, Benito-Villalvilla C, Díez-Rivero CM, Cases B, Manzano AI, Fernández-Caldas E, Casanovas M, Palomares O, Subiza JL. Allergy. 2018 Apr;73(4):875-884. doi: 10.1111/all.13396. Epub 2018 Jan 31.

Novel vaccines targeting dendritic cells by coupling allergoids to mannan.

Benito-Villalvilla, C., Soria, I., Subiza, J.L. et al. Allergo J Int (2018). https://doi.org/10.1007/s40629-018-0069-8

La entrada Novel allergoid-mannan vaccine in veterinary medicine se publicó primero en Inmunotek.

Source: Inmunotek News

RETOS-COLABORACION 2017 Grant

You need to login to view this content. Please Login

RETOS-COLABORACION 2017 Grant

RETOS-COLABORACION 2017 Grant
{$excerpt:n}

09/2018. RETOS-COLABORACION Project Granted

The Spanish Ministry of Science, Innovation and Universities has granted the funding of the research project RTC-2017-6271-1 applied by INMUNOTEK together with the Foundation of the Institute of Studies of Health Sciences of Castilla y León.

The project is focused to a technological development to quantify a new tumor serum marker with clinical utility for the early diagnosis of patients with prostate cancer.

Prostate cancer affects an increasing number of men for demographic reasons (aging of the population) and also because the treatments allow a greater control of the disease. Although PSA levels in the blood can detect cancer in early stages, the values ​​can also increase in benign prostate diseases. This is fueling the search of other biomarkers able to complement the information offered by the PSA.

La entrada RETOS-COLABORACION 2017 Grant se publicó primero en Inmunotek.

Source: Inmunotek News